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Background: Brain metastases occur in up to 75% of patients with advanced melanoma. Most are treated with whole-
brain radiotherapy (WBRT), with limited effectiveness. Vandetanib, an inhibitor of vascular endothelial growth factor
receptor, epidermal growth factor receptor and rearranged during transfection tyrosine kinases, is a potent radiosensitiser in
xenograft models. We compared WBRT with WBRT plus vandetanib in the treatment of patients with melanoma brain
metastases.
Methods: In this double-blind, multi-centre, phase 2 trial patients with melanoma brain metastases were randomised to receive
WBRT (30Gy in 10 fractions) plus 3 weeks of concurrent vandetanib 100mg once daily or placebo. The primary endpoint was
progression-free survival in brain (PFS brain). The main study was preceded by a safety run-in phase to confirm tolerability of the
combination. A post-hoc analysis and literature review considered barriers to recruiting patients with melanoma brain metastases
to clinical trials.
Results: Twenty-four patients were recruited, six to the safety phase and 18 to the randomised phase. The study closed early
due to poor recruitment. Median PFS brain was 3.3 months (90% confidence interval (CI): 1.6–5.6) in the vandetanib group and
2.5 months (90% CI: 0.2–4.8) in the placebo group (P¼ 0.34). Median overall survival (OS) was 4.6 months (90% CI: 1.6–6.3) and
2.5 months (90% CI: 0.2–7.2), respectively (P¼ 0.54). The most frequent adverse events were fatigue, alopecia, confusion
and nausea. The most common barrier to study recruitment was availability of alternative treatments.
Conclusions: The combination of WBRT plus vandetanib was well tolerated. Compared with WBRT alone, there was no significant
improvement in PFS brain or OS, although we are unable to provide a definitive result due to poor accrual. A review of barriers to
trial accrual identified several factors that affect study recruitment in this difficult disease area.
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The incidence of melanoma is increasing, both in the UK and
worldwide. It is now the fifth most common cancer in the United
Kingdom, and second most common cancer in adults aged 25–49
(Cancer Research UK statistics, 2009–2011). Early detection and
treatment with surgical excision leads to cure in the majority of
cases, but in about 15% of patients the disease metastasises. In
patients with metastatic melanoma, spread to the brain has been
reported in up to 75% of cases, and melanoma is the third most
common cancer to metastasise to the brain, after lung and breast
cancer (Davies et al, 2011). Median overall survival (OS) in patients
diagnosed with melanoma brain metastases is about 4 months,
with the brain metastases considered contributing to death in over
90% of cases (Fife et al, 2004).
Traditionally, most patients have been treated with palliative whole-
brain radiotherapy (WBRT), which provides symptomatic benefit, but
no significant survival benefit (Davies et al, 2011). Trials of the cytotoxic
agents fotemustine and temozolomide, alone or in combination with
WBRT, have produced responses in a minority of patients, but again no
significant survival benefit (Mornex et al, 2003; Agarwala et al, 2004;
Hofmann et al, 2006; Atkins et al, 2008). More recently, in patients with
limited tumour burden (generally three or fewer brain lesions),
treatment with surgical excision or stereotactic radiosurgery (SRS) has
improved survival to 8–9 months (Fife et al, 2004; Davies et al, 2011;
Chowdhury et al, 2015). The immunomodulating CTLA-4 inhibitor
ipilimumab is effective in some patients with asymptomatic/stable
brain metastases (Ajithkumar et al, 2015), whilst the BRAF
inhibitors vemurafenib and dabrafenib produce responses in BRAF
mutant melanoma patients with symptomatic brain metastases
(Long et al, 2012; Dummer et al, 2014). Trials of newer
immunomodulating PD-1/PDL-1 inhibitors in patients with brain
metastases are ongoing. Nonetheless, the management of melanoma
brain metastases, especially for patients with multiple lesions, continues
to represent an area of significant unmet medical need, and most trials
of new agents exclude patients with active CNS disease.
Vandetanib is an orally bioavailable anti-angiogenic small molecule
receptor tyrosine kinase inhibitor that targets vascular endothelial
growth factor receptor (VEGFR), epidermal growth factor receptor
(EGFR) and rearranged during transfection (RET) tyrosine kinases
(Morabito et al, 2009). It has demonstrated anti-tumour activity in
melanoma, lung and prostate cancer xenografts (Wedge et al, 2002;
Langenkamp et al, 2012), and is licensed for the treatment of
medullary thyroid cancer (Bible and Ryder, 2016). In a mouse
model of melanoma brain metastases, vandetanib monotherapy
demonstrated effective inhibition of angiogenesis but limited effect
on tumour growth (Leenders et al, 2004). The effect of vandetanib on
tumour vasculature and oxygenation has been found to enhance the
efficacy of radiotherapy in lung and head and neck cancer xenografts
(Shibuya et al, 2007; Gustafson et al, 2008). Vandetanib 100mg once
daily was found to be the maximum tolerated dose when combined
with WBRT and temozolomide in a phase 1 trial of patients with
glioblastoma (Drappatz et al, 2010).
The aim of this study was to compare WBRT alone with WBRT
plus vandetanib in the treatment of patients with melanoma brain
metastases.
MATERIALS AND METHODS
Study design and patients. This randomised, double-blind, placebo-
controlled, multi-centre phase 2 trial (ISRCTN 20253034) was
conducted at seven hospitals across the UK under the auspices of
the National Cancer Research Institute Melanoma Clinical Study
Group. The randomised phase was preceded by a safety run-in phase
of six patients who all received WBRT plus vandetanib 100mg once
daily, to confirm tolerability in this patient population. Tolerability
was defined as no treatment related toxicity of grade 3 or more
(as per NCI CTCAE version 4.03) up to 30 days post end of study
treatment in at least 5 out of 6 patients in the safety run-in phase.
Patients were eligible if aged 18 years or older, with advanced
melanoma with brain metastases (excluding leptomeningeal
disease and ocular malignant melanoma), Karnofsky Performance
Score of 70% or higher, Radiation Therapy Oncology Group
(RTOG) recursive partitioning analysis (RPA) score of 1 or 2
(Gaspar et al, 2000), and adequate cardiac, bone marrow, renal,
and liver function. All patients needed to have at least one lesion in
the brain measurable at study entry as per Response Evaluation
Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer et al,
2009). Patients were ineligible if they had received any radio-
therapy or systemic melanoma therapy within 28 days before
starting study treatment. They were also excluded if they had ever
received previous WBRT, or if all brain metastases had been
previously treated by neurosurgery or SRS. A stipulation of no
more than three extra-cranial metastatic sites at screening was
removed after the safety run-in phase.
All patients provided written informed consent and the study
was conducted in accordance with the UK Clinical Trials
Regulations and the ICH guidelines of Good Clinical Practice.
The protocol was approved by the independent South Central
Hampshire B Research Ethics Committee and by review boards at
each study site.
Randomisation and masking. Eligible patients were randomised
1 : 1 to receive WBRT plus vandetanib or WBRT plus placebo,
stratifying for RPA score (1 vs 2), using an Interactive Web
Response System. Patients and clinicians were kept blinded to the
treatment allocation. Vandetanib/placebo was supplied as 100mg
white film-coated tablets packed in high-density polyethylene
bottles.
Procedures. Radiotherapy was administered via parallel opposed
lateral beams dosed to the midpoint as 30Gy in 10 fractions over 2
weeks. Patients in the safety run-in phase all received vandetanib
100mg once daily, starting 4 days (±1 day) before WBRT and
continuing for 21 days in total. Patients in the randomised phase
received vandetanib/placebo as above. If a patient developed
significant QT prolongation, or any CTCAE grade 3/4 toxicity
considered related to study treatment, vandetanib/placebo was
withheld until the toxicity improved to grade 1 or baseline, after
which study drug was restarted at a reduced dose of 100mg once
every alternate day. No study drug was given beyond day 21, even
if doses were missed in between.
Endpoints. The primary endpoint was progression-free survival in
the brain (PFS brain), assessed by magnetic resonance imaging
(MRI) scan using RECIST version 1.1, and defined as time from
date of randomisation to date of progression or date of death from
any cause, whichever was first. Secondary endpoints included OS,
defined as time from date of randomisation to date of death,
proportion of patients alive and progression-free in brain at 6
months (APF6), as estimated from the Kaplan–Meier plots, and
safety and tolerability. Patients without a PFS or OS event were
censored at date of last assessment.
Assessments. Tumour response was based on investigator assess-
ment of brain metastases as per RECIST 1.1, using MRI at baseline,
30 days post treatment, and then at 2 monthly intervals, until 12
months post randomisation or progression in the brain, whichever
was first. After this, patients were followed for survival only.
Adverse events (AEs) were graded according to NCI CTCAE
version 4.03. All patients receiving any study medications were
included in the safety analyses.
Statistical analysis. For the randomised phase we originally
planned to conduct the primary analysis after recruitment of 80
patients and B74 brain progression/death events had occurred.
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Assuming a hazard ratio (HR) of 0.6 (likely to correspond to a 70%
prolongation of PFS brain), this analysis would have 80% power
with a one-sided significance level of 0.01 to demonstrate a
statistically significant difference in PFS brain between the two
treatment arms. It was estimated that this number of events would
occur B4 months after the planned 2-year recruitment period.
However, due to poor study accrual, recruitment was closed early,
meaning that the previously calculated target of 80 patients was not
reached. We completed primary and secondary analyses as
planned, but adequate evaluation of the benefit of vandetanib in
addition to WBRT was not possible due to lack of numbers.
All survival analyses were on an intention-to-treat (ITT) basis,
and involved all patients recruited to the randomised phase.
Treatment arms were compared for PFS brain and OS using Cox
regression analysis. APF6 was compared between treatment groups
using the Kaplan–Meier estimates. Analyses were undertaken using
Stata version 13.1 (StataCorp, College Station, TX, USA).
Barriers to accrual. Following study closure due to poor accrual
we performed a literature review to better understand the factors
affecting recruitment to trials of WBRT. We interrogated PubMed
using the search terms ‘WBRT’, ‘WBRTþmelanoma’ and
‘WBRTþ accrual’, limited to clinical trials performed within the
last 10 years. Results were hand sorted for relevance by title and
abstract. Relevant papers were then mined for additional results by
reviewing internal references and registered citations on PubMed.
To identify factors specific to the RADVAN study we also
circulated a questionnaire to all participating sites, following
closure to recruitment, asking what factors investigators thought
affected their ability to recruit to RADVAN. Specifically we asked
Assessed for eligibility (N =71)
Excluded (N =47)
Not meeting inclusion criteria (n=33)
Declined to participate (n=12) 
Other (n=2) 
Analysed intention to treat: N=10
Excluded from ITT analysis (n=0)
Analysed per protocol: N=7
Excluded from PP analysis (n=3)
Analysed safety of vandetanib: N=16
Lost to follow-up (n=0)





Allocated to experimental intervention (N=10)
Received allocated intervention (n=9)
Did not start treatment (n=1)
Lost to follow-up (n=0)





Allocated to control intervention (N=8)
Received allocated intervention (n=7)
Did not start treatment (n=1)
Analysed Intention to treat: N=8
Excluded from ITT analysis (n=0)
Analysed per protocol: N=2













Figure 1. RADVAN study CONSORT flow diagram.
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for the reasons for not screening potentially eligible patients and
whether increased use of neurosurgery or SRS and the availability
of vemurafenib and ipilimumab affected recruitment.
RESULTS
Patients. Between December 2011 and April 2014 there were
71 patients screened across seven sites, of which six were recruited
to the safety phase (completed February 2013), and 18 were
recruited to the randomised phase, which closed in April 2014 due
to lack of accrual (Figure 1). The most common reasons for
patients failing screening were poor performance status and the
choice of alternative treatment (15% and 9% of patients who failed
screening respectively). For the randomised phase, 10 patients were
allocated to WBRT plus vandetanib and eight to WBRT plus
placebo. Baseline characteristics were well balanced between the
treatment groups (Table 1).
Safety run-in phase. Six eligible patients were recruited to the
safety phase of the trial. One patient did not complete the full
course of study drug and was non-evaluable, leaving five evaluable
patients. None of these five patients experienced grade 3 or more
toxicity considered related to study treatment. Therefore, WBRT
30Gy in 10 fractions plus vandetanib 100mg OD for 21 days was
considered tolerable and the study proceeded to the randomised
phase.
Efficacy. For the randomised phase, the primary endpoint of PFS
brain was analysed at the closure of the trial, at which point
median follow-up for all patients was 4.5 months. As per ITT
analysis, median PFS brain was 3.3 months (90% confidence
interval (CI): 1.6–5.6) in patients randomised to WBRT plus
vandetanib and 2.5 months (90% CI: 0.2–4.8) in patients
randomised to WBRT plus placebo (Figure 2A, Table 2). Although
lack of numbers precluded accurate assessment of significance,
from the data available there was no statistically significant
difference in PFS brain between the two treatment groups, with an
unadjusted HR of 0.65 (90% CI: 0.29–1.45; P¼ 0.34, Tarone–Ware
test). With 17 deaths recorded at analysis, median OS was 4.6
months (90% CI: 1.6–6.3) in patients randomised to the
vandetanib group and 2.5 months (90% CI: 0.2–7.2) in the placebo
group, with a HR of 0.85 (90% CI: 0.37–1.96; P¼ 0.54; Figure 2B,
Table 2). The APF6 was 20% in the vandetanib group and 13% in
the placebo group (Table 2).
Compliance. For the randomised phase, 7 out of 10 patients
(70%) in the vandetanib group completed 21 days of study drug
compared with 2 out of 8 patients (25%) in the placebo group.
In the vandetanib group, 8 out of 10 patients completed all 10 days
of WBRT compared with 4 out of 8 patients in the placebo group.
For the majority of patients not completing WBRT in both
treatment arms, the reason was disease progression.
Safety and tolerability. For the safety analysis, all patients who
received WBRT plus vandetanib, in both the safety and
randomised phases, were included. The most frequent AEs were
fatigue, alopecia, confusion and nausea (Table 3). Of the total
number of AEs, 14% were CTCAE grades 3 and 4. In the
vandetanib group three patients developed grade 3 confusion, one
developed grade 3 QT prolongation and one developed grade 3
constipation. In total 11 serious adverse events (SAEs) occurred;
four in the safety run-in phase, five in those randomised to
vandetanib and two in those randomised to placebo. The most
common SAE was confusion. All deaths were disease related.
Barriers to accrual. The most common reason given by study
investigators for not screening potentially eligible patients for this
study was preference for alternative treatments. For BRAF mutant
melanoma patients with brain metastases, most investigators opted
for oral BRAF inhibitor treatment first. For BRAF wild-type
melanoma patients with brain metastases, some investigators
elected to treat with immunotherapy first, if the brain metastases
were small and asymptomatic. Increased use of neurosurgery/SRS,
poor prognosis and rapid deterioration were also cited as common
reasons for not recruiting patients.
Table 1. Baseline characteristics
Characteristic WBRTþ vandetanib (N¼10) WBRTþplacebo (N¼8) Safety cohort (N¼6)
Age at randomisation (years)
Mean (min–max) 57 (42–77) 64 (44–83) 69 (55–77)
Gender, n (%)
Male 5 (50) 3 (37.5) 4 (66.7)
Female 5 (50) 5 (62.5) 2 (33.3)
Karnofsky performance status
100 2 (20) 1 (12.5) 1 (16.7)
90 5 (50) 5 (62.5) 2 (33.3)
80 2 (20) 2 (25) 3 (50)
70 1 (10) 0 0
Past melanoma treatment, n (%)
Prior surgery 10 (100) 7 (87.5) 6 (100)
Prior medical therapy 6 (60) 6 (75) 2 (33.3)
Prior radiotherapy 3 (30) 1 (12.5) 2 (33.3)
Any extra-cranial metastases, n (%)
Yes 10 (100) 7 (87.5) 5 (83.3)
No 0 1 (12.5) 1 (16.7)
RTOG RPA score, n (%)
1 0 0 1 (16.7)
2 10 (100) 8 (100) 5 (83.3)
Sum of LAD of target lesions in brain
Median (IQR) 29 (16) 31 (22.5) 30 (25)
Abbreviations: IQR¼ interquartile range; LAD¼ long-axis dimension; RTOG RPA¼Radiation Therapy Oncology Group recursive partitioning analysis; WBRT¼whole-brain radiotherapy.
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Our review of the literature identified seven published studies
of WBRT for brain metastases (melanoma or otherwise) in the last
10 years that failed to reach their recruitment target (Roos et al,
2006; Neuhaus et al, 2009; Chua et al, 2010; Hassler et al, 2013;
Robins et al, 2013; Sperduto et al, 2013; Niravath et al, 2015).
It is reasonable to expect there are more that have not
been published. We identified four key themes around failure
to recruit:
Reluctance to refer patients for WBRT studies. A number of
investigators noted that referring clinicians often have strong
anecdotal preferences on whether or not to refer patients with
brain metastases for WBRT, based on concerns over WBRT-
related toxicities, and melanoma traditionally being viewed as a
radio-resistant disease (Roos et al, 2006; Redmond et al, 2008;
Fogarty et al, 2014). With this in mind, Fogarty et al undertook a
wide consultation amongst clinicians treating melanoma when
setting up their phase 3 trial of WBRT after local treatment of
melanoma brain metastases (Fogarty et al, 2011). This helped raise
awareness of the proposed study, and identified potential concerns
recruiting physicians may have.
For a phase 3 study in patients with non-small-cell lung cancer
(NSCLC) brain metastases comparing optimal supportive care (OSC)
with OSC plus WBRT, the investigators took a different approach.
Slow accrual was thought at least partially due to lack of evidence
supporting the hypothesis that OSC alone is non-inferior to OSC plus
WBRT, leading to a reluctance to refer patients for the study. So the
investigators chose to release interim data, to help inform both
patients and clinicians considering study entry (Langley et al, 2013).
Following release of the interim data, which supported the study
hypothesis, recruitment improved from an average of 6.9 patients per
month to 8.8 patients per month (Stephens et al, 2014).
PFS brain
Overall survival
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Figure 2. Kaplan–Meier curve for (A) PFS brain and (B) OS by treatment group.
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Availability of alternative treatments. Increased availability of
alternative treatments for melanoma brain metastases, namely
neurosurgery, SRS, immunotherapy and BRAF inhibitors, has
affected recruitment to trials of WBRT, as these alternatives are
seen by both patients and clinicians as offering higher chance of
benefit and a more appealing side effect profile than WBRT
(Ajithkumar et al, 2015). Similar issues have affected accrual to
WBRT studies in other tumour types, such as NSCLC (Sperduto
et al, 2013; Welsh et al, 2013).
Site selection and overestimation of ability to recruit. Careful
selection of study sites with proven ability to recruit within the
desired patient population, possession of full on-site treatment
facilities and multi-disciplinary clinics, is considered crucial for
successful recruitment (Neuhaus et al, 2009; Langley et al, 2013;
Fogarty et al, 2014). Central coordination of site set-up and ethics
submissions have also been identified as important for successful
study accrual (Fogarty et al, 2014).
As part of their phase 3 trial of WBRT after local treatment of
melanoma brain metastases, Fogarty et al (2014) undertook a pilot
study to assess if accrual to the main study was feasible. Through
this they identified that even study sites with proven track records
for accrual to melanoma trials often overestimated how many
patients they could recruit. The degree of overestimation was less if
based on reviewing past records, rather than memory recall. The
majority of sites reduced their estimated recruitment figure when
asked to sign a research contract that included a prediction of
patient recruitment. Despite this, out of 19 sites only 4 succeeded
in recruiting to within 50% of what they had specified in the
research contract (Fogarty et al, 2014).
Differences in time to study treatment initiation have been
found to vary between sites, with another phase 3 trial of patients
with NSCLC brain metastases noting that North American sites on
average started treatment more promptly than European/Austra-
lian sites, primarily because their patients were randomised more
quickly, with 60% randomised within 2 weeks of diagnosis of brain
metastases at North American sites, compared with 32% at
European/Australian sites (Mehta et al, 2009).
The importance of sensitive study design. Many investigators felt
sensitive study design, which balanced accrual against both a
patient’s ability and a site’s ability to complete the trial and provide
assessable data, is key to encouraging site interest in recruitment as
well as patient interest in participation. Study entry criteria in this
patient group are generally quite strict, which can limit successful
accrual (Neuhaus et al, 2009; Chua et al, 2010; Niravath et al,
2015). In a phase 3 study of WBRT vs WBRT plus thalidomide, a
short window between diagnosis of brain metastases and need to
start treatment, and a requirement for follow-up with MRI scans
every 2 months to assess PFS brain were noted to affect
recruitment at some study sites (Knisely et al, 2008). Restrictions
on post-protocol treatment can also hinder recruitment, as
described in another phase 3 study of NSCLC patients with brain
metastases, where the original protocol stipulated further treatment
could only be given at time of progressive disease or after 6 months
(Sperduto et al, 2013).
DISCUSSION
The combination of WBRT 30Gy in 10 fractions plus vandetanib
100mg once daily is straightforward to administer and well
tolerated in patients with melanoma brain metastases. Median PFS
brain was increased with the combination, but the low numbers of
patients recruited and lack of statistical power to detect differences
between treatment arms prevented adequate evaluation of the
combination. Data on BRAF mutation status were not collected in
this study. However, increasing evidence that BRAF/NRAS status
and activation of the PI3K/AKT pathway have a role in the
development of melanoma brain metastases means establishing
tumour molecular profile will be important in future studies
(Chen et al, 2014; Johnson et al, 2015).
Recruitment was expected to take 2 years, but proved more
challenging than anticipated. Recruiting six patients to the safety
phase alone took 12 months. Even after relaxing entry criteria
(by removing the stipulation of no more than three extra-cranial
metastatic sites at screening, following feedback from sites that this
Table 2. Main efficacy results
Parameters WBRTþ vandetanib WBRTþplacebo One-sided P-value
PFS brain (months)
Median (90% CI) 3.3 (1.6–5.6) 2.5 (0.2–4.8) 0.339
Overall survival (months)
Median (90% CI) 4.6 (1.6–6.3) 2.5 (0.2–7.2) 0.537
PFS rate in brain at 6 months
Estimated % (90% CI) 20 (5–43) 13 (1–37) 0.693
Abbreviations: PFS¼progression-free survival; WBRT¼whole-brain radiotherapy.















Fatigue 6 (38) 0 4 (50) 0
Alopecia 5 (31) 0 0 0
Confusion 4 (25) 3 (19) 0 0
Nausea 4 (25) 0 0 0
Headache 3 (19) 0 0 0
Constipation 2 (13) 1 (6.3) 0 0
Rash 2 (13) 0 4 (50) 0
Cough 2 (13) 0 2 (25) 0
Diarrhoea 2 (13) 0 1 (13) 0
QT prolongation 1 (6.3) 1 (6.3) 0 0
Blurred vision 1 (6.3) 0 1 (13) 0
Atrial fibrillation 1 (6.3) 0 0 0
Pericardial effusion 1 (6.3) 0 0 0
Other 9 (56) 3 (19) 4 (50) 4 (50)
Abbreviations: AE¼ adverse event; WBRT¼whole-brain radiotherapy.
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had excluded patients who would otherwise have been suitable),
only 18 patients were recruited to the randomised phase over a
further period of 12 months. Following review by the RADVAN
Trial Management Group in April 2014, it was decided that the
slow rate of recruitment meant the study would not be able to yield
meaningful results within a reasonable timeframe, and so it was
closed to further recruitment. This decision was supported by the
Independent Early Phase Trials Oversight Committee, AstraZeneca
and the national Clinical Trials Awards and Advisory Committee.
The field of melanoma is evolving rapidly, with increasing
treatment options available with the potential for activity against
melanoma brain metastases as well as extra-cranial disease. The
most common reason cited by investigators for not screening
potentially eligible patients for the RADVAN study was preference
for alternative treatments. Nonetheless, there remain no clear
guidelines for management of melanoma brain metastases, with
treatment decisions often based on physician and patient
preference, rather than robust trial data. In such a rapidly evolving
field adaptive clinical trial designs, which can incorporate new
treatment strategies based on emerging clinical data, are likely to be
key to ensuring successful study recruitment and meaningful
outcomes (Zang and Lee, 2014).
A literature review of other studies of WBRT for brain
metastases identified a number of other factors that affect study
recruitment. Fogarty et al (2011) concluded that international
participation is essential to ensure adequate recruitment to trials
of melanoma brain metastases. The BREAK-MB study demon-
strated how international trials can recruit patients with
melanoma brain metastases very successfully, with 172 patients
enroled over a 7-month period from 24 centres in six countries
(Long et al, 2012). However, several international studies of both
melanoma and lung cancer brain metastases have failed, or
struggled, to meet their recruitment targets, indicating that this
alone is not enough (Chua et al, 2010; Langley et al, 2013;
Fogarty et al, 2014). Identifying realistic recruitment targets is
important, and the approach taken by Fogarty et al of
encouraging sites to provide feasibility forecasts based on
reviewing past records, rather than estimating from memory,
and including the predicted recruitment number in the research
contract, may help (Fogarty et al, 2014). Strategies such as clear
and sensitive study design in consultation with clinicians
responsible for patient recruitment, along with careful selection
of study sites have also helped overcome competition from
alternative treatments and bias within the medical community to
ensure successful study recruitment.
In summary, recruitment to RADVAN proved more
challenging than expected, partly due to increased treatment
options available for such patients, and partly because
many patients were not fit enough to start study treatment.
A number of factors have been identified which affect
recruitment to trials of WBRT. These factors need to be
carefully considered when designing future clinical trials for
this patient population.
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